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Background: Recently, an intra-patient comparison demonstrated that the somatostatin (sst) ligand
[68Ga]HA-DOTATATE ([68Ga]DOTA-3-iodo-Tyr3-octreotate) provides PET images comparable to or superior to those
obtained with [68Ga]DOTATATE. To provide a comprehensive basis for nevertheless observed slight differences in
tracer biodistribution and dosimetry, the characteristics of [68Ga]HA-DOTATATE were investigated in a detailed
preclinical study.
Methods: Affinities of natGa-HA-DOTATATE and natGa-DOTATATE to sst1–5 were determined using membrane
preparations and [125I]SST-28 as radioligand. Internalization into AR42J cells was studied in dual-tracer studies with
[125I]TOC as internal reference. Biodistribution was investigated using AR42J tumor-bearing CD1 mice, and specificity
of tracer uptake was confirmed in competition studies by coinjection of 0.8 mg TOC/kg.
Results: Sst2 affinities (IC50) of [
natGa]HA-DOTATATE (1.4 ± 0.8 nM, logP: −3.16) and [natGa]DOTATATE (1.2 ± 0.6 nM,
logP: −3.69) were nearly identical. Both compounds displayed IC50 > 1 μM for sst1,3,4, while sst5 affinity was
markedly increased for natGa-HA-DOTATATE (102 ± 65 nM vs >1 μM for natGa-DOTATATE). [natLu]HA-DOTATATE
and [natLu]DOTATATE showed slightly lower, identical sst2 affinities (2.0 ± 1.6 and 2.0 ± 0.8 nM, respectively) and
sst3 affinities of 93 ± 1 and 162 ± 16 nM. Internalization of [
68Ga]HA-DOTATATE was tenfold higher than that of
[125I]TOC but only sixfold higher for [68Ga]DOTATATE and [177Lu]HA-DOTATATE. While [68Ga]HA-DOTATATE and
[68Ga]DOTATATE had shown similar target- and non-target uptake in patients, biodistribution studies in mice at 1 h post
injection (n = 5) revealed slightly increased non-specific uptake of [68Ga]HA-DOTATATE in the blood, liver, and intestines
(0.7 ± 0.3, 1.0 ± 0.2, and 4.0 ± 0.7 %iD/g vs 0.3 ± 0.1, 0.5 ± 0.1, and 2.7 ± 0.8 %iD/g for [68Ga]DOTATATE). However, sst-
mediated accumulation of [68Ga]HA-DOTATATE in the pancreas, adrenals, and tumor was significantly enhanced (36.6 ±
4.3, 10.8 ± 3.2, and 33.6 ± 10.9 %iD/g vs 26.1 ± 5.0, 5.1 ± 1.4, and 24.1 ± 4.9 %iD/g, respectively). Consequently,
tumor/background ratios for [68Ga]HA-DOTATATE in the AR42J model are comparable or slightly increased
compared to [68Ga]DOTATATE.
Conclusions: The present preclinical data fully confirm the general biodistribution pattern and excellent in vivo
sst-targeting characteristics previously observed for [68Ga]HA-DOTATATE in patients. The effect of slightly enhanced
lipophilicity on background accumulation and normal organ dose is compensated by the high uptake of
[68Ga]HA-DOTATATE in tumor. Thus, [68Ga]HA-DOTATATE represents a fully adequate, freely available substitute for
[68Ga]DOTATATE and, given the superb sst-targeting characteristics of [177Lu]HA-DOTATATE in vitro, potential applicability
for sst-targeted PRRT.
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Figure 1 Schematic representation of the structures of
DOTATATE and HA-DOTATATE.
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The excellent suitability of 68Ga-labeled octreotide analogs
for functional imaging of somatostatin (sst) receptor-
overexpressing tumors is well documented throughout the
literature and has been thoroughly reviewed in recent
publications [1,2]. Both [68Ga]DOTATOC- ([68Ga]DOTA-
Tyr3-octreotide) and [68Ga]DOTATATE- ([68Ga]DOTA-
Tyr3-octreotate) PET have been established as the imaging
modality of choice for the diagnosis and management of
patients with neuroendocrine tumors (NETs). Of the
two tracers, [68Ga]DOTATATE shows slight advan-
tages with respect to normal organ distribution, while
tumor detection rates are identical to those of [68Ga]
DOTATOC [3]. Recently, [68Ga]DOTANOC ([68Ga]
DOTA-Nal3-octreotide) has also entered the clinical
arena [4]. Due to its high affinity to sst2, sst3 and sst5, sig-
nificantly more and smaller lesions are detected using
[68Ga]DOTANOC compared to the sst2-selective high-
affinity ligand [68Ga]DOTATATE, suggesting it to be the
preferred agent for the imaging application [5].
However, in the context of sst-targeted endoradiother-
apy using the respective 177Lu- or 90Y-labeled peptides,
[177Lu]DOTATATE compared favorably to [177Lu]
DOTANOC [6]. Due to its high sst2 selectivity,
[177Lu]DOTATATE showed significantly lower uptake/
dose delivered to normal tissues, while there were no sig-
nificant differences concerning tumor kinetics and mean
absorbed tumor dose. Thus, in the context of patient se-
lection for sst-targeted endoradiotherapy with [177Lu]
DOTATATE, [68Ga]DOTATATE-PET represents the im-
aging strategy of choice for an accurate assessment of sst
expression levels.
Unfortunately, the availability of DOTATATE is gov-
erned by patent restrictions. With the intent to provide
a suitable alternative with unchallenged in vivo perform-
ance, we recently introduced [68Ga]HA-DOTATATE
([68Ga]high-affinity DOTATATE, i.e., [68Ga]DOTA-3-
iodo-Tyr3-octreotate, Figure 1). In the first in vitro stud-
ies, Ga-HA-DOTATATE had shown unchangedly high
sst2 affinity compared to Ga-DOTATATE and increased
affinity to sst5 [7]. Given that the physicochemical
properties of [68Ga]HA-DOTATATE are very similar
to those of [68Ga]DOTATATE, we directly transferred
[68Ga]HA-DOTATATE into the first patients. Intra-
patient comparison of [68Ga]DOTATATE- and [68Ga]
HA-DOTATATE-PET revealed slightly enhanced uptake
of the high-affinity analog in sst-expressing tissues as well
as a marginally increased accumulation in the excretion
organs. These characteristics lead to a remarkably
uniform performance of [68Ga]DOTATATE and [68Ga]
HA-DOTATATE in PET imaging of sst-expressing NETs
[8]. However, not unexpectedly, the observed slight in-
crease in specific and non-specific tissue accumulation of
[68Ga]HA-DOTATATE leads to somewhat higher organdoses compared to [68Ga]DOTATATE [9]. To provide a
basis for understanding the underlying reasons for these
differences and thus for the adequate interpretation of our
observations in patients, we performed a detailed preclin-
ical evaluation of [68Ga]HA-DOTATATE in comparison to
[68Ga]DOTATATE. Envisaging its potential use in peptide
receptor radiotherapy, [177Lu]HA-DOTATATE was also in-
cluded in the in vitro evaluation for a first comparative as-
sessment of its binding and internalization characteristics.Methods
Peptide synthesis
General conditions
2-CTC (2-chlorotrityl chloride) resin, coupling reagents
as well as most Fmoc amino acids were obtained from
Iris Biotech (Marktredwitz, Germany). Fmoc-3-iodo-
Tyr and (Leu8,D-Trp22,[125I]Tyr25)-somatostatin-28 were
supplied by Bachem (Heidelberg, Germany). All other or-
ganic reagents were purchased from VWR (Darmstadt,
Germany) or Sigma-Aldrich or Fluka (Munich, Germany).
Solvents were used without further purification. Solid
phase peptide synthesis was carried out manually
using an Intelli-Mixer syringe shaker (Neolab, Heidelberg,
Germany).
Analytic RP-HPLC was performed on a Nucleosil 100
C18 (5 μm, 125 × 4.0 mm internal diameter (i.d.)) column
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ent HPLC System (Sykam, Fürstenfeldbruck, Germany).
The peptides were eluted applying various gradients of
0.1% TFA (trifluoroacetic acid) in H2O (solvent A) and
0.1% TFA in acetonitrile (solvent B) over 15 min at a
constant flow of 1 mL/min. Preparative RP-HPLC was
performed on the same HPLC system using a Multospher
100 RP 18–5 (250 × 10 mm i.d.) column (CS GmbH,
Langerwehe, Germany) at a constant flow of 5 mL/min.
UV detection was performed at 220 nm using a 206 PHD
UV–vis detector (Linear™ Instruments Corporation, Reno,
NV, USA). For radioactivity measurement, the outlet
of the UV photometer was connected to a NaI(Tl) well-
type scintillation counter from EG&G Ortec (München,
Germany). Radio-TLC was carried out using a Varian sil-
ica impregnated ITLC chromatography paper (Varian
Inc., Palo Alto, CA, USA) and a 1:1 (v/v) mixture of 1 M
aq. NH4OAc and MeOH as mobile phase. TLC strips
were analyzed using a miniGita TLC analyzer (Raytest,
Straubenhardt, Germany).
Mass spectra were recorded on the LC-MS system
LCQ from Finnigan (Bremen, Germany) using a Hewlett
Packard series 1100 HPLC system (Agilent Technologies
Inc., Santa Clara, CA, USA).
DOTATATE and HA-DOTATATE
DOTATATE and HA-DOTATATE were synthesized ac-





assembled on 2-CTC resin using a standard Fmoc proto-
col. After cleavage from the solid support using TFA/
H2O/TIBS (triisobutylsilane) (95/2.5/2.5 (v/v/v)), the Lys
5
(Dde)-protected peptides were cyclized using H2O2 in an
aqueous THF (tetrahydrofurane) solution at pH 7. DOTA
coupling was carried out in aqueous DMF (dimethylfor-
mamide) solution using unprotected DOTA and NHS and
EDCI as coupling reagents. Subsequent removal of the
Lys5(Dde) protecting group was carried out using 2% of
hydrazine hydrate in DMF. Crude peptides were then
purified via preparative HPLC.
DOTATATE (C65H90N14O19S2):
calculated monoisotopic mass = 1,434.6
Found: m/z= 1,436.1 [M+H]+, m/z= 1,458.0 [M+Na]+,
718.8 [M+ 2H]2+
HA-DOTATATE (C65H89N14IO19S2):
calculated monoisotopic mass = 1,560.5
Found: m/z = 1,561.6 [M +H]+, m/z= 1,583.5 [M+Na]+
Synthesis of natGa, natLu, and natY reference compounds
DOTATATE and HA-DOTATATE (200 to 500 μg) were
dissolved in 20 mM GaNO3, LuCl3, or YCl3 solution (in0.01 M HCl), respectively, to yield a final peptide con-
centration of 1 mM. After heating to 95°C for 30 min in
a sealed tube, HPLC analysis revealed quantitative com-
plex formation without side products. The product solu-
tions were used as such for the preparation of dilution
series for binding studies.
natGa-DOTATATE (C65H88N14O19S2Ga):
calculated monoisotopic mass = 1,501.6
Found: m/z = 752.6 [M + 2H]2+
natGa-HA-DOTATATE (C65H87N14IO19S2Ga):
calculated monoisotopic mass = 1,628.5
Found: m/z = 1,629.1 [M +H]+, 1,651.0 [M +Na]+,
814.2 [M + 2H]2+
natLu-DOTATATE (C65H87N14O19S2Lu):
calculated monoisotopic mass = 1,606.6
Found: m/z = 804.6 [M + 2H]2+
natLu-HA-DOTATATE (C65H86N14IO19S2Lu):
calculated monoisotopic mass = 1,732.5
Found: m/z = 867.5 [M + 2H]2+
natY-HA-DOTATATE (C65H86N14IO19S2Y):
calculated monoisotopic mass = 1,646.5
Found: m/z = 1,647.2 [M +H]+, 1,669.1 [M +Na]+,
824.2 [M + 2H]2+
Radiolabeling
68Ga labeling
68Ga-labeling of DOTATATE and HA-DOTATATE
(5 nmol) was carried out in a fully automated, GMP-
compliant procedure using a Scintomics Gallelut+ module
(Scintomics, Fürstenfeldbruck, Germany) [11,12]. Briefly, a
68Ge/68Ga generator with SnO2 matrix (iTHEMBA LABS,
South Africa) was eluted with 1.0 M aq. HCl, and in order
to minimize the reaction volume, a fraction of 1.25 mL
containing approx. 80% of the eluted 68Ga activity was used
for the labeling reaction. HEPES (3.7 M, 800 μL) was used
to adjust the pH of the reaction mixture to pH 3. After
heating to 95°C for 5 min, the reaction mixture was passed
through a SPE cartridge (SepPak® C18, Waters, Eschborn,
Germany). The cartridge was washed with water and the
68Ga-labeled peptides were eluted in a small volume of
ethanol. For in vitro studies, the product fraction was di-
luted with PBS and used as such for further dilutions. For
the in vivo biodistribution studies, the ethanol content of
the product solution was evaporated in vacuo.
For quality control, radio-TLC was carried out using a
Varian silica impregnated glass fiber TLC chromatography
paper (Agilent Technologies, Waldbronn, Germany) and a
1:1 (v/v) mixture of 1 M aq. NH4OAc and MeOH as mo-
bile phase. TLC strips were analyzed using a BioScan TLC
analyzer (BioScan, Tucson, AZ, USA).
177Lu labeling
For 177Lu-complexation, c.a. 177LuCl3 (85 MBq,
approx. 20 μL, SA 1100 GBq/mg) in 0.05 M HCl
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to an Eppendorf vial, and 22.5 μL of DOTA-peptide
(100 μM in water, 2.25 nmol, 4.5 molar equivalents over
177Lu as calculated from the specific activity at the day of
the experiment) was added. The mixture was diluted with
NH4OAc (0.1 M) to a total volume of 200 μL (pH= 5 in
the final reaction mixture) and heated to 95°C for 30 min.
Upon cooling to room temperature and determination of
the labeling yield using Radio-TLC, the labeling mixture
was directly diluted with assay buffer to a final peptide
concentration of 20 nM and used as such for the subse-
quent in vitro studies.
Radioiodination of (Leu8,D-Trp22,Tyr25)-somatostatin-28 and
Tyr3-octreotide
Radioiodination of (Leu8,D-Trp22,Tyr25)-somatostatin-28
and Tyr3-octreotide (TOC) was carried out using the
IodoGen® method. Briefly, 200 μg of peptide were
dissolved in 0.5 mL TRIS iodination buffer (25 mM
Tris–HCl, 0.4 M NaCl, pH 7.5) and transferred to an
Eppendorf reaction tube coated with 150 μg of
IodoGen®. Upon addition of [125I]NaI (18 to 20 MBq,
Hartmann Analytik, Braunschweig, Germany), the reac-
tion vessel was briefly vortexed, and the labeling reaction
was allowed to proceed for 15 min at RT. The peptide
solution was then removed from the insoluble oxidizing
agent. Separation of the radioiodinated peptides from
unlabeled precursor was achieved using gradient RP-
HPLC (gradient: 22% to 37% solvent B within 20 min,
flow: 1 mL/min). For the subsequent in vitro studies, the
respective HPLC product fraction was used as such and
diluted to the required concentration using assay buffer.
Determination of lipophilicity
Lipophilicities of [68Ga]DOTATATE/HA-DOTATATE
and [177Lu]DOTATATE/HA-DOTATATE were deter-
mined via a modified shake flask method as described
previously [13].
In vitro studies
Determination of IC50 using cell membranes
Cell membrane preparations of cells expressing the hu-
man sst1–5 were obtained from Millipore (Schwalbach,
Germany) and PerkinElmer (Rodgau, Germany). Competi-
tion binding studies were performed in close analogy to
the manufacturer’s protocol. Briefly, solutions of unlabeled
competitor (natGa-DOTATATE, natLu-DOTATATE,
natGa-HA-DOTATATE, natLu-HA-DOTATATE; 10 μL,
concentration range from 1 × 10−11 to 1 × 10−4 M, n = 3
per concentration and peptide) in binding buffer (50 mM
HEPES, 5 mM MgCl2, 1 mM CaCl2, 0.2% BSA, buffered to
pH 7.4 using 1 N NaOH) were pipetted into a 96-well
plate. To each well, 10 μL of (Leu8,D-Trp22,[125I]Tyr25)-
somatostatin-28 in binding buffer (approx. 100,000 cpm)were added. Then, 5 μg of cell membrane in 80 μL of
binding buffer were added per well and incubated for
60 min at RT. The final radioligand concentration in
the incubation mixture was 0.42 nM. Membranes
were then aspired onto a glass fiber filtermat (Printed
Filtermat B, Wallach, Turku, Finland), which had been
preconditioned with 0.33% polyethylenimine for 30 min
and then washed five times with 300 μL (per well) of
wash buffer (50 mM HEPES, 500 mM NaCl, 0.1% BSA,
buffered to pH 7.4 using 1 N NaOH), using a Mach II M
Harvester 96 (Tomtec CE, Etten-Leur, The Netherlands).
Membranes were washed ten times with 150 μL (per
well) of wash buffer. The filtermat was then cut into
squares containing the membrane from the respective
wells, and membrane bound activity was counted in
a γ-counter. IC50 values were calculated from bound
activity [cpm] using PRISM 6 software (Graph Pad
Software, San Diego, CA, USA).
Dual-tracer internalization studies using AR42J cells
AR42J cells (rat pancreatic adenocarcinoma) were ob-
tained from ECACC (European Collection of Cell
Cultures, Salisbury, UK). Cells were maintained in RPMI
1640 (Biochrom, Berlin, Germany) supplemented with
10% FCS (Seromed-Biochrom, Berlin, Germany) and
2 mM L-glutamine (Gibco BRL Life Technologies,
Karlsruhe, Germany). Cells were maintained at 37°C
in a 5% CO2/humidified air atmosphere. In the assay
medium used for internalization studies, FCS was replaced
by 5% BSA (Sigma-Aldrich, Munich, Germany).
To avoid the influence of inter-experimental variations
in cell count and cell viability on absolute internalization
data, all internalization experiments were performed as
dual-tracer studies using [125I]TOC as an internal refer-
ence. Experiments were carried out as previously de-
scribed with minor modifications [14]. Briefly, after
preconditioning of the cells (approx. 200,000 cells/well)
with 200 μL of assay medium for a minimum of
15 min, 25 μL (per well) of either assay medium
(total internalization) or 50 μM unlabeled TOC (non-
specific internalization) were added, followed by the
addition of 25 μL of assay medium containing a mixture
of the respective 68Ga/177Lu-labeled DOTA-peptide and
[125I]TOC, respectively. Final concentrations of 68Ga/
177Lu-peptide and [125I]TOC in the assay medium were 1
nM (68Ga)/2 nM (177Lu) and 0.1 nM, respectively, and
were calculated based on the specific activities of the
radioligands used. After incubation at 37°C for different
time points up to 60 min, the incubation medium was
removed, and cells were rinsed with 250 μL of unsupple-
mented medium. The combined medium fractions repre-
sent the amount of free radioligand. Receptor bound
(acid releasable) radioactivity was then removed using
2 × 250 μL of ice cold acid wash buffer (0.02 M NaOAc
Table 1 Lipophilicities of [68Ga]DOTATATE and







Partition coefficients (logPO/PBS) of the radioligands between PBS (pH 7.4) and
n-octanol were determined using a shake flask method (n = 6) [13].
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was released by incubation with 250 μL of 1 N NaOH,
transferred to vials and combined with 250 μL of PBS
used for rinsing the wells. Quantification of the amount
of free, acid-releasable, and internalized activity was per-
formed in a γ-counter. Data for total internalized ligand
(mean ± SD) were corrected by non-specific internaliza-
tion (mean ± SD) at the respective time point using Excel
considering the laws of error propagation.
Biodistribution experiments
All animal experiments were performed in accord with
current animal welfare regulations in Germany (approval
#55.2-1-54-2532-71-13).
AR42J tumor model
To establish tumor growth, AR42J cells were detached
from the surface of the culture flasks using 1 mM EDTA
in PBS, centrifuged, and resuspended in serum-free cul-
ture medium. Concentration of the cell suspension was
2.5 to 5 × 106 cells/100 μL. Nude mice (CD-1 nu/nu, fe-
male, 6 to 8 weeks, from Charles River WIGA GmbH,
Sulzfeld, Germany) were injected with 100 μL of the cell
suspension subcutaneously into the flank. Ten days after
tumor transplantation, all mice showed solid palpable
tumor masses (tumor weight 20 to 90 mg) and were
used for the experiments.
Biodistribution studies
The 68Ga-labeled peptides, 1.1 to 1.7 MBq (depending
on the respective specific activity of the radiotracer;
the peptide amount per mouse was kept constant at
25 pmol) in 100 μL of PBS (pH 7.4), were injected i.v.
into the tail vein of nude mice bearing an AR42J tumor.
For competition studies, 20 μg TOC (0.8 mg/kg) were
coinjected with the radioligands. The animals (groups of
4 to 5) were sacrificed 1 h post injection and the organs
of interest were dissected. The radioactivity was mea-
sured in weighted tissue samples using a γ-counter. Data
are given in %iD/g and are means ± SD.
Results and discussion
Radiolabeling
The synthesis of [68Ga]DOTATATE and [68Ga]HA-
DOTATATE was performed according to an optimized
protocol, yielding both tracers in >99% radiochem-
ical purity and specific activities (SA) of 62 ± 11 and
68 ± 10 GBq/μmol, respectively. [177Lu]HA-DOTATATE
was obtained in the same radiochemical purity but with a
lower SA of 38 GBq/μmol due to the comparably low spe-
cific activity of the 177Lu used.
Radioiodination via the IodoGen® method afforded the
reference ligands [125I]TOC and [Leu8,D-Trp22,[125I]Tyr25]-
somatostatin 28 in radiochemical purities >99% andyields of 68 ± 4% and 54 ± 5% after HPLC purification,
respectively. Since the HPLC conditions applied
allowed very efficient separation of the radioiodinated
products from the unlabeled precursors (ΔtR ≥ 5 min)
and no co-eluting carrier peak was observed in the
labeled peptide peak in the quality control UV chro-
matograms, the specific activity of [125I]TOC and
[Leu8,D-Trp22,[125I]Tyr25]-somatostatin 28 was as-
sumed to be that of the radioiodide used for their
preparation (≥74 GBq/μmol).
Lipophilicity
The lipophilicities of the respective 68Ga- and 177Lu-
complexes of DOTATATE and HA-DOTATATE are
summarized in Table 1. As expected, iodine-for-
hydrogen substitution in Tyr3 leads to an increase in
lipophilicity of the [68Ga/177Lu]HA-DOTATATE ana-
logs compared to their respective DOTATATE coun-
terparts. Furthermore, both 177Lu-labeled compounds
display an enhanced lipophilicity compared to their
corresponding 68Ga analogs. This was also anticipated
based on the documented different geometries of the
68Ga-DOTA and the 177Lu-DOTA chelates. While all
carboxylate pendant arms of DOTA (in addition to the
DOTA-peptide-amide bond) are involved in the 177Lu-
DOTA complex for complete saturation of the coord-
ination sphere of 177Lu, one of the carboxylate pen-
dant arms is free in the 68Ga-DOTA complexes [15].
In vitro studies
IC50 studies using membrane preparations (sst1–5)
Affinities (IC50 in nM) of the respective
natGa and natLu
complexes of DOTATATE and HA-DOTATATE as well
as natY-HA-DOTATATE for hsst1–5 are summarized in
Table 2. Data were determined using membrane prepa-
rations of CHO cells stably transfected with the respect-
ive sst subtype. Since in our earlier studies [7,8] only
preliminary results (n = 2 experiments) had been pub-
lished, further experiments were performed to validate
these data.
In comparison to the previously published affinities,
absolute IC50 values are slightly increased when averaging
Table 2 Affinity profiles of the natGa, natLu, and natY complexes of DOTATATE and HA-DOTATATE for hsst1-hsst5 receptors
Peptide hsst1 hsst2 hsst3 hsst4 hsst5
natGa-DOTATATE >1,000 (2) 1.2 ± 0.6 (5) >1,000 (2) >1,000 (3) >1,000 (3)
natLu-DOTATATE >1,000 (2) 2.0 ± 0.8 (5) 162 ± 16 (2) >1,000 (3) >1,000 (3)
natGa-HA-DOTATATE >1,000 (2) 1.4 ± 0.8 (5) >1,000 (2) >1,000 (3) 102 ± 65 (4)
natLu-HA-DOTATATE >1,000 (2) 2.0 ± 1.6 (5) 93 ± 1 (2) >1,000 (3) 222 ± 148 (4)
natY-HA-DOTATATE n.d. 2.4 ± 0.3 (2) n.d. n.d. 680 (1)
Affinity profiles were determined using membrane preparations of CHO cells stably transfected with the respective sst subtype (supplier: Millipore) and
[Leu8,D-Trp22,[125I]Tyr25]-somatostatin 28 as the radioligand. Values represent IC50 ± SD [nM]; the number of independent experiments is shown in parentheses.
n.d., not determined.
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natGa-DOTATATE and natGa-HA-DOTATATE as well
as the corresponding natLu pair, respectively, have identical
and high hsst2 affinities, with slightly lower affinities of the
natLu-peptides (as well as natY-HA-DOTATATE) com-
pared to the corresponding natGa analogs. This observa-
tion is in agreement with previous studies by Reubi et al.
[16] and Antunes et al. [4] that demonstrated a gen-
erally enhanced sst2 affinity of various sst-targeted
natGa-DOTA-octapeptides over their respective natLu/
natY/natIn analogs. It is important to note, however,
that the absolute IC50 values obtained in the present
study using membrane preparations (Table 2) are sub-
stantially higher than those obtained by Reubi et al. for
natGa-DOTATATE and natY-DOTATATE using receptor
autoradiography (0.20 ± 0.04 and 1.6 ± 0.4 nM, respect-
ively) [16]. The reduced ‘sensitivity’ of our experimental
setup might also explain why natGa-DOTATATE and
natLu-DOTATATE showed virtually no hsst4 and hsst5
affinity in this study, while affinities in the range of
200 to 500 nM were observed in the autoradiography
assay [16].
In this context, the confirmed substantially enhanced
hsst5 affinities of
natGa-/natLu-HA-DOTATATE com-
pared to the respective DOTATATE analogs, which rep-
resents the rationale for terming these compounds
‘high-affinity DOTATATE’ (HA-DOTATATE), are even
more noteworthy.
Unfortunately, at the time of the second series of
experiments, the hsst3 ChemiSCREEN® membrane
(Millipore, Schwalbach, Germany) preparation was
not available from the manufacturer anymore, and
therefore, the data set for this sst subtype could not be
completed under the original experimental conditions.
To nevertheless be able to fully evaluate the sst subtype
specificities of natGa-/natLu-HA-DOTATATE, mem-
brane preparations from CHO-K1 cells transfected with
hsst2–5 were purchased from an alternative supplier
(PerkinElmer), and experiments were repeated under
experimental conditions identical to the previous ex-
periments in triplicate. Unexpectedly, absolute IC50
values were found to be generally increased by a factorof 2.5 to 3.5 compared to the values obtained using the
ChemiSCREEN® membranes, independently of the hsst
subtype assayed. For example, hsst2A affinities deter-
mined for natGa- and natLu-DOTATATE and natGa-,
natLu-, and natY-HA-DOTATATE in this assay were
2.9 ± 0.6, 7.3 ± 2.6, 3.8 ± 1.0, 6.6 ± 1.4, and 6.7 ± 0.1 nM,
respectively. Despite the upward shift in absolute IC50
values, these data very well reflect the relative affinities
determined using the ChemiSCREEN® membranes. The
same was also observed for the data obtained for hsst3–5.
Thus, despite the limited numerical compatibility of
the two separate data sets, both satisfactorily reflect the
important differences in the sst subtype affinity profiles
of the different DOTATATE and HA-DOTATATE ana-
logs, namely the substantially enhanced hsst5 (and hsst3)
affinities of the HA-DOTATATE compounds. Therefore,
the data in Table 2 were deemed satisfactorily significant
to serve as representative values.
Dual-tracer internalization studies
Comparative internalization studies for [68Ga]DOTATATE,
[68Ga]HA-DOTATATE and [177Lu]HA-DOTATATE were
carried out using AR42J rat pancreatic carcinoma cells
(RPMI-1640 medium (5% BSA), 37°C). To eliminate the in-
fluence of inter-experimental variations in cell count and cell
viability on absolute tracer uptake, all studies were carried
out as dual-tracer studies using [125I]TOC as an internal ref-
erence. Radioligand concentrations were 1 nM for the 68Ga-
labeled compounds, 2 nM for [177Lu]HA-DOTATATE (to
ensure acceptable count rates despite lower specific
activity) and 0.1 nM for [125I]TOC in all experiments.
To ensure accurate data normalization, the same [125I]
TOC preparation was used for all experiments in this
series.
An improved internalization efficiency of radiolabeled
TATE analogs compared to the respective TOC or OC an-
alogs is well documented throughout the literature
[14,17,18]. Thus, as expected, all radiometallated TATE an-
alogs in this study showed significantly enhanced internal-
ization compared to the internal standard [125I]TOC.
At all time points, internalization efficiency was
highest for [68Ga]HA-DOTATATE (1,000 ± 113% of
Schottelius et al. EJNMMI Research  (2015) 5:22 Page 7 of 10[125I]TOC), followed by [68Ga]DOTATATE (570 ± 49%
of [125I]TOC) and [177Lu]HA-DOTATATE (425 ± 45% of
[125I]TOC). Interestingly, the difference in internal-






































































































Figure 2 Internalization of [68Ga]DOTATATE, [68Ga]HA-DOTATATE,
[177Lu]HA-DOTATATE, and the internal reference [125I]TOC into
AR42J cells. Data are means ± SD (n= 3) and are corrected for
non-specific internalization in the presence of 5 μM unlabeled TOC.HA-DOTATATE nicely reflects the difference in sst2 affin-
ity of the compounds (Table 2) and is in accordance with
results from the literature [4]. In contrast, the almost dou-
bled internalization of [68Ga]HA-DOTATATE compared to
[68Ga]DOTATATE was unexpected, considering their iden-
tical sst2 affinities. However, it has already been demon-
strated that internalization efficiency of TATE analogs does
not necessarily correlate with sst2 affinity [14,19]. Further-
more, the fact that the sst2 affinities were determined in
membrane preparations expressing the human receptor,
while internalization studies were carried out using rat-sst2-
expressing AR42J cells, might also contribute to the dis-
crepancies observed between binding and internalization
data (Figure 2).
Biodistribution studies
Biodistribution data for [68Ga]DOTATATE and
[68Ga]HA-DOTATATE in AR42J tumor-bearing nude
mice at 60 min post injection (p.i.) are summarized
in Table 3.
Compared to [68Ga]DOTATATE, [68Ga]HA-DOTATATE
displays a slightly delayed blood clearance, which is accom-
panied by an increased non-specific accumulation in the ex-
cretion organs, especially in the liver and intestine. These
combined effects are most probably due to the enhanced
lipophilicity of [68Ga]HA-DOTATATE compared to
[68Ga]DOTATATE (Table 1), leading to both a higher
fraction of plasma protein binding [20] and a slight
shift of renal towards hepatobiliary excretion. Gener-
ally, the non-specific tracer distribution and excretion
pattern observed for [68Ga]HA-DOTATATE in AR42JTable 3 Biodistribution of [68Ga]DOTATATE and
[68Ga]HA-DOTATATE in AR42J tumor-bearing nude mice
at 60 min p.i.
[68Ga]DOTATATE [68Ga]HA-DOTATATE
Control Competition Control Competition
Blood 0.3 ± 0.06 0.4 ± 0.2 0.7 ± 0.3 2.5 ± 0.6
Heart 0.3 ± 0.04 0.2 ± 0.1 0.5 ± 0.2 1.0 ± 0.2
Lung 8.4 ± 1.4 0.6 ± 0.2 13.2 ± 1.0 2.5 ± 0.4
Liver 0.5 ± 0.1 0.2 ± 0.05 1.0 ± 0.2 1.0 ± 0.3
Intestine 2.7 ± 0.8 0.6 ± 0.2 4.0 ± 0.7 0.8 ± 0.04
Kidney 3.9 ± 0.5 4.1 ± 0.9 5.3 ± 1.0 17.1 ± 8.7
Spleen 0.9 ± 0.1 0.2 ± 0.03 1.9 ± 0.8 0.7 ± 0.2
Muscle 0.3 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 0.6 ± 0.4
Stomach 15.9 ± 3.9 0.7 ± 0.1 21.7 ± 4.5 1.9 ± 0.8
Adrenals 5.1 ± 1.4 0.4 ± 0.1 10.8 ± 3.2 1.0 ± 0.3
Pancreas 26.1 ± 4.9 0.6 ± 0.03 36.6 ± 4.3 1.5 ± 0.5
AR42J tumor 24.1 ± 4.9 2.0 ± 0.1 33.6 ± 10.9 5.6 ± 0.7
For control experiments, animals (n = 5 per group) were injected with tracer
only. For competition experiments, 20 μg/mouse of unlabeled TOC were
coinjected with the respective radioligand (n = 3 per group). Data are
































coinjection of 20 µg TOC
[68Ga]HA-DOTATATE 
coinjection of 20 µg TOC
Figure 3 Sst-specific tissue uptake of [68Ga]DOTATATE and [68Ga]HA-DOTATATE. Effect of coinjection of 20 μg of unlabeled TOC per
mouse (0.8 mg/kg) on the uptake of [68Ga]DOTATATE and [68Ga]HA-DOTATATE in sst-positive normal tissues and tumor of AR42J tumor-bearing
nude mice at 60 min p.i. Data are means ± SD with n = 5 in the control experiment and n = 3 in the competition experiment.
Schottelius et al. EJNMMI Research  (2015) 5:22 Page 8 of 10tumor-bearing mice fully mirror the observations made
in our previously published comparative PET imaging
and dosimetry studies in patients [7-9].
Due to its enhanced internalization efficiency,
[68Ga]HA-DOTATATE shows high uptake in sst-
expressing mouse tissues such as the stomach, adrenals,
pancreas, and the AR42J tumor xenografts (increased by a
factor of 1.4 to 2 compared to [68Ga]DOTATATE) [21]. Sst
specificity of tracer uptake in these organs was confirmed
in a competition study by coinjection of an excess of un-
labeled TOC (Table 3 and Figure 3). Interestingly, sst-


























Figure 4 Tumor-to-organ ratios of [68Ga]DOTATATE and [68Ga]HA-D
tumor-bearing nude mice (60 min p.i.). Data are means ± SD (n = 5).lung, spleen, and intestines both for [68Ga]DOTATATE
and [68Ga]HA-DOTATATE, underlining the suitability of
both radioligands for the sensitive in vivo detection of
even low sst expression levels. Of the two compounds
investigated, [68Ga]HA-DOTATATE showed a slightly
higher proportion of non-blockable tissue uptake in the
competition study, reflecting the higher blood activity
concentration of this compound under the experimental
conditions.
Again, the preclinical mouse data obtained in this
study parallel the findings from our human PET studies,




OTATATE. Biodistribution experiments were carried out in AR42J
Schottelius et al. EJNMMI Research  (2015) 5:22 Page 9 of 10sst-targeting efficiency compared to [68Ga]DOTATATE,
reflected by a slight increase in SUVmean for the spleen
and pituitary [8]. However, while the mouse biodistribu-
tion data in this study reveal fundamental differences
between both the general biodistribution and sst-
mediated tissue accumulation of [68Ga]HA-DOTATATE
and [68Ga]DOTATATE, respectively, these opposed ef-
fects were not observed to the same extent in the hu-
man studies. For example, tracer uptake (SUVmean) in
normal organs such as the liver and kidney as well as
in primary tumors and their metastases were found to
be nearly identical for both radioligands in patients [8].
Obviously, tissue distribution of [68Ga]HA-DOTATATE
and [68Ga]DOTATATE in humans is mainly dominated
by the very similar tracer pharmacokinetics of both
compounds, whereas in mice, the respective influence
of both the increased sst-targeting efficiency and of the
slightly enhanced lipophilicity of [68Ga]HA-DOTATATE
on tracer biodistribution is much more pronounced.
Interestingly, the comparable in vivo performance of
[68Ga]HA-DOTATATE and [68Ga]DOTATATE in pa-
tients is well reflected by the very similar tumor-to-
background ratios (Figure 4) obtained for the two
compounds in the AR42J xenograft model. Here, the
high sst-targeting efficiency of [68Ga]HA-DOTATATE is
counterbalanced by the enhanced tracer accumulation
in non-target organs occasioned by the delayed clear-
ance kinetics of [68Ga]HA-DOTATATE. It is important
to note that, given the early time point after tracer in-
jection (1 h p.i.), these data certainly do not display the
full sst-targeting potential of [68Ga]HA-DOTATATE. Its
increased blood activity levels at 1 h p.i. may lead to
improved bioavailability and even higher tumor uptake
at later time points, which might prove advantageous
for PRRT using [177Lu]HA-DOTATATE. However,
longer circulation times also might entail increased
hematotoxicity, and therefore, it needs to be carefully
evaluated in preclinical therapeutic studies, to what ex-
tent the differences between [177Lu]DOTATATE and
[177Lu]HA-DOTATATE will have an impact on the
therapeutic effects of the compounds.
Conclusions
The previous observations from our patient studies
demonstrating nearly identical performance of
[68Ga]HA-DOTATATE and [68Ga]DOTATATE in
PET have now been complemented and confirmed
by detailed comparative preclinical results. [68Ga]
HA-DOTATATE shows enhanced internalization
in vitro and at least equal in vivo tumor targeting
compared to [68Ga]DOTATATE. Based on unlimited
precursor availability, [68Ga]HA-DOTATATE there-
fore represents a useful alternative to other cur-
rently used 68Ga-labeled somatostatin analogs and,as suggested by affinity and internalization data,
may have potential for targeted radiotherapy using,
e.g., 177Lu. To assess its suitability for this applica-
tion, however, careful evaluation taking into account
the slightly altered pharmacokinetics of HA-
DOTATATE compared to DOTATATE and the po-
tential risks associated therewith is warranted.
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